西班牙瓦伦西亚地区C群脑膜炎球菌抗体血清流行率:C群脑膜炎球菌结合疫苗接种的影响
该血清流行病学研究于2010年10月至2012年4月在西班牙瓦伦西亚地区开展,检测1880名≥3岁受试者血清杀菌抗体(SBA)滴度≥8的比例。在接种C群脑膜炎球菌结合疫苗(MCCV)后8-12年,仅约三分之一受种者具有血清保护,不同接种程序间保护率差异明显。
要点
- 1880名受试者中523名(27.8%)SBA滴度≥8,具有血清保护。
- 10-13岁补种 campaign 接种者(采血时20-21岁)血清保护率最高,为67.8%(95%CI 56.9-77.4)。
- 2、4、6月龄婴儿期常规免疫者(采血时7-8岁)血清保护率最低,为7.1%(95%CI 3.3-13.1)。
核心结论
- 接种MCC疫苗8-12年后,仅约三分之一受种者具有血清保护。
- 血清流行率研究对识别易感人群和指导疫苗政策至关重要。
研究设计与样本
- 血清流行病学研究,2010年10月至2012年4月在西班牙瓦伦西亚地区开展。
- 样本量按年龄组预期血清保护率而非人口比例确定,检测≥3岁受试者血清SBA滴度。
- 共采集1880名受试者血清样本,采用标准化补体介导血清杀菌抗体试验检测。
- 以SBA滴度≥8定义为血清保护,采用多因素logistic回归模型评估疫苗接种对血清保护的影响。
主要发现
- 1880名受试者中523名(27.8%)具有保护性SBA滴度。
- 1430名<30岁受试者(任一疫苗接种活动目标人群)中446名(31.2%)具有保护性SBA滴度。
- 10-13岁补种campaign接种者(采血时20-21岁)血清保护率最高,为67.8%(95%CI 56.9-77.4)。
- 2、4、6月龄婴儿期常规免疫者(采血时7-8岁)血清保护率最低,为7.1%(95%CI 3.3-13.1)。
- 12月龄后接种一剂疫苗与血清保护增加相关,接种年龄越大与血清保护持续时间越长呈正相关。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Meningococcal C conjugate (MCC) vaccination programs provide direct and indirect protection against meningococcal disease. However, a decrease in the antibodies could affect herd immunity. We conducted a seroprevalence study to assess the immunity in subjects 8-12years after different MCCV vaccination programs were launched and evaluated the impact of vaccination on seroprotection. METHODS: Seroepidemiological study conducted from October 2010 to April 2012 in the region of Valencia, Spain. Sample size was not proportional to the population but to the expected seroprotection by age group. Sera from subjects that were≥3years old were tested using a standardized complement-mediated serum bactericidal antibodies (SBA) assay. Age-stratified proportions of subjects with SBA titers≥8 were considered seroprotected and evaluated. A multivariate logistic regression model was performed to evaluate the impact of vaccination on the seroprotection. RESULTS: Serum samples from 1880 subjects were collected. In total, 523 (27.8%) of the 1880 subjects and 446 (31.2%) of the 1430 subjects<30years (targeted to any vaccination campaign) showed protective SBA titers. The highest percentage of seroprotected subjects (67.8%, 95%CI 56.9-77.4) was observed in those that were vaccinated in a catch-up campaign at 10-13years of age (20-21years old at the time of blood sampling). Those scheduled for immunization in infancy at 2, 4 and 6months of age (7-8years at blood sample) represented the lowest (7.1%, 95% CI 3.3-13.1) number of seroprotected subjects. Having received one vaccine dose after 12months of age was associated with increased seroprotection. The present study revealed a positive correlation between the increasing age at vaccination and longer duration of seroprotection. CONCLUSION: Only one in three subjects who were vaccinated with MCC vaccine was seroprotected after 8-12years. These findings emphasize that seroprevalence studies are essential to identify susceptible cohorts and to inform vaccine policy.
引用
- Pérez-Breva L, Abad-Torreblanca R, Martínez-Beneito MÁ, et al. Seroprevalence of antibodies against serogroup C meningococci in the region of Valencia, Spain: Impact of meningococcal C conjugate vaccination. Vaccine. 2017. PMID: 28438407. doi:10.1016/j.vaccine.2017.04.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。